GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » EV-to-EBITDA

Nascent Biotech (Nascent Biotech) EV-to-EBITDA : -14.16 (As of May. 13, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nascent Biotech's enterprise value is $16.44 Mil. Nascent Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.16 Mil. Therefore, Nascent Biotech's EV-to-EBITDA for today is -14.16.

The historical rank and industry rank for Nascent Biotech's EV-to-EBITDA or its related term are showing as below:

NBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -230.18   Med: -22.35   Max: 9.2
Current: -14.16

During the past 7 years, the highest EV-to-EBITDA of Nascent Biotech was 9.20. The lowest was -230.18. And the median was -22.35.

NBIO's EV-to-EBITDA is ranked worse than
100% of 465 companies
in the Biotechnology industry
Industry Median: 9.34 vs NBIO: -14.16

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), Nascent Biotech's stock price is $0.0995. Nascent Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.015. Therefore, Nascent Biotech's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Nascent Biotech EV-to-EBITDA Historical Data

The historical data trend for Nascent Biotech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech EV-to-EBITDA Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial -3.96 -3.11 -10.71 -46.65 -7.08

Nascent Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.31 -7.08 77.45 -20.59 -24.70

Competitive Comparison of Nascent Biotech's EV-to-EBITDA

For the Biotechnology subindustry, Nascent Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Biotech's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's EV-to-EBITDA falls into.



Nascent Biotech EV-to-EBITDA Calculation

Nascent Biotech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=16.440/-1.161
=-14.16

Nascent Biotech's current Enterprise Value is $16.44 Mil.
Nascent Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nascent Biotech  (OTCPK:NBIO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nascent Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0995/-0.015
=At Loss

Nascent Biotech's share price for today is $0.0995.
Nascent Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.015.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Nascent Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nascent Biotech (Nascent Biotech) Business Description

Traded in Other Exchanges
N/A
Address
631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Executives
Lowell Thomas Holden director, officer: CFO 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick director, officer: President 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price director, officer: Senior VP Business Development 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas director 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy director, officer: CEO 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121